The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: Implications for gene therapy and vaccines using AAV1 vector

Journal of Medical Virology

Volumn 85, Issue 9, 2013, Pages 1550-1556

  Liu, Qiang ^a   Huang, Weijin ^a   Zhao, Chenyan ^a   Zhang, Li ^a   Meng, Shufang ^a   Gao, Dongying ^b   Wang, Youchun ^a  

^a BEIJING HOSPITAL   (China)

^b Beijing Blood Center   (China)

Author keywords

AAV1; Gene therapy; Neutralizing antibody; Vaccine

Indexed keywords

ADENO ASSOCIATED VIRUS SEROTYPE 1 NEUTRALIZING ANTIBODY; LUCIFERASE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ADULT; AGE; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; GENE TRANSFER; GEOGRAPHIC ORIGIN; GUINEA PIG; HUMAN; HUMAN CELL; NORMAL HUMAN; PREVALENCE; SEX DIFFERENCE; VACCINATION; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS NEUTRALIZATION;

AAV1; GENE THERAPY; NEUTRALIZING ANTIBODY; VACCINE;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHINA; CROSS-SECTIONAL STUDIES; DEPENDOVIRUS; DRUG CARRIERS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; YOUNG ADULT;

EID: 84880351298     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23647     Document Type: Article

References (20)

1. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2 5, 6 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors Hum Gene Ther 21:704-712.
2. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. 2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199:381-390.
3. Dong X, Tian W, Wang G, Dong Z, Shen W, Zheng G, Wu X, Xue J, Wang Y, Chen J. 2010. Establishment of an AAV reverse infection-based array. PLoS ONE 5:e13479.
4. Grimm D, Kay MA. 2003. From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3:281-304.
5. Lin J, Zhi Y, Mays L, Wilson JM. 2007. Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol 81:11840-11849.
6. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM. 2008. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 19:663-669.
7. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. 2006. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24:198-204.
8. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 12:342-347.
9. Nathwani AC, Gray JT, McIntosh J, Ng CY, Zhou J, Spence Y, Cochrane M, Gray E, Tuddenham EG, Davidoff AM. 2007. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109:1414-1421.
10. Peden CS, Burger C, Muzyczka N, Mandel RJ. 2004. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 78:6344-6359.
11. Petry H, Brooks A, Orme A, Wang P, Liu P, Xie J, Kretschmer P, Qian HS, Hermiston TW, Harkins RN. 2008. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 15:54-60.
12. Riviere C, Danos O, Douar AM. 2006. Long-term expression and repeated administration of AAV type 1, 2, and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13:1300-1308.
13. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF. 2006. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107:1810-1817.
14. Tenenbaum L, Lehtonen E, Monahan PE. 2003. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 3:545-565.
15. van der Marel S, Comijn EM, Verspaget HW, van Deventer S, Van Den Brink GR, Petry H, Hommes DW, Ferreira V. 2011. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: Implications for gene therapy. Inflamm Bowel Dis 17:2436-2442.
16. Vincent T, Harvey BG, Hogan SM, Bailey CJ, Crystal RG, Leopold PL. 2001. Rapid assessment of adenovirus serum neutralizing antibody titer based on quantitative, morphometric evaluation of capsid binding and intracellular trafficking: Population analysis of adenovirus capsid association with cells is predictive of adenovirus infectivity. J Virol 75:1516-1521.
17. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. 1999. Gene therapy vectors based on adeno-associated virus type 1. J Virol 73:3994-4003.
18. Yang L, Li Y, Zhang LF, Feng X, Yu SQ, Chen DY, Li ZL, Zeng Y. 2011. Study on vector-specific and foreign gene-specific immune responses induced by rAd5 and rAAV2/1 vaccines. Chin J Exp Clin Virol 25:431-433.
19. Zaiss AK, Muruve DA. 2005. Immune responses to adeno-associated virus vectors. Curr Gene Ther 5:323-331.
20. Zaiss AK, Muruve DA. 2008. Immunity to adeno-associated virus vectors in animals and humans: A continued challenge. Gene Ther 15:808-816.